Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Bradstock Kenneth, Emma Link, DPhil, Juliana Di Iulio, BAppSc, PhD, Jeff Szer, MB, BS, FRACP, Paula Marlton, MBBS, FRCPA, FRACP, Andrew Wei, MBBS, PhD, Arno Enno, MB,BS,FRCPA, FRACP, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Ian D. Lewis, MBBS PhDFRACP FRCPA, James D'Rozario, MB BS FRACP, Luke Coyle, MBBS, FRACP, FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Philip Campbell, MB ChB FRACP FRCPA, Michael Francis Leahy, FRACP, Uwe H Hahn, MDFGCP FRCPA, Paul Cannell, MD, Campbell Tiley, MBBS,FRACP, FRCPA, Raymond M. Lowenthal, MD FRACP, FRCP, John Moore, MBBS, MD FRACP , FRCPA, Kimberly Cartwright, FRACP,MDFRCPA, Ilona Cunningham, John Taper, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Andrew W. Roberts, MBBS PhD, Warwick John Benson, Mark S Hertzberg, MBBS PhDFRACP FRCPA, Sandra F. Deveridge, MDBSc,FRACP,FRCPA, Philip Arthur Rowlings, FRACP,FRCPA,MBBS,MS, Anthony K. Mills, MBBS, FRACP, FRCPA, Devinder S Gill, MBChB FRCPath MRCP, Peter G Bardy, MBBS, FRACP, FRCPA, Lynda Campbell, John F. Seymour, MD

Blood (2016) 128 (22): 338.

https://doi.org/10.1182/blood.V128.22.338.338

Published: 2016

Journal Articles

Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial

Suneet Sandhu, MBBS, MPH, FRACP, FRCPA, Devinder Gill, MB FRCPath FRACP FRCPA, Paul David Turner, MBBS, FRACP, FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Leanne Berkahn, MD, David R Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Cecily Forsyth, MBBS, FRACP, FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Rosemary Harrup, MBBS, FRACP, FRCPA, Giles Best, BSc, PhD, Mathias Bressel, MSc, Juliana Di Iulio, BAppSc, PhD, Bryone Jean Kuss, PhD MBBS, FRCPA, FRACP, Stephen Mulligan, MBBS, PhD FRACP, FRCPA

Blood (2015) 126 (23): 5295.

https://doi.org/10.1182/blood.V126.23.5295.5295

Published: 2015

Journal Articles

Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL)

Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA, Devinder Gill, MB, FRCPath, FRACP, FRCPA, Paul Turner, MBBS FRACP FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MB BS, FRACP, FRCPA, Leanne Berkahn, MD, David R Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Cecily J Forsyth, MB BS, FRACP, FRCPA, Gavin Cull, MBBS, DM, FRACP, FRCPA, Rosemary Harrup, MB BS, FRACP, FRCPA, Melanie Sulda, B.Sc, PhD, Giles Best, BSc (Hons), PhD, Mathias Bressel, MSc, Juliana Di Iulio, BAppSc, PhD, Bryone J Kuss, MBBS, PhD FRCPA, FRACP

Blood (2014) 124 (21): 4695.

https://doi.org/10.1182/blood.V124.21.4695.4695

Published: 2014

Journal Articles

A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity

Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA, Devinder Gill, MB, FRCPath, FRACP, FRCPA, Paul Turner, MBBS FRACP FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MB BS FRACP FRCPA, Leanne Berkahn, MD, David Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Cecily J Forsyth, MB BS, FRACP, FRCPA, Gavin Cull, MBBS, DM, FRACP, FRCPA, Rosemary Harrup, MB BS, FRACP, FRCPA, Melanie Sulda, B.Sc, PhD, Giles Best, BSc (Hons), PhD, Mathias Bressel, MSc, Juliana Di Iulio, BAppSc, PhD, Bryone J Kuss, MBBS, PhD FRCPA, FRACP

Blood (2014) 124 (21): 3325.

https://doi.org/10.1182/blood.V124.21.3325.3325

Published: 2014

Journal Articles

High Dose Cytarabine (HiDAC) and Fludarabine Without Anthracycline For Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): The Australasian Leukaemia and Lymphoma Group (ALLG) AMLM13 Study

Paula Marlton, MBBS, John F Seymour, MBBS, PhD, Kenneth Bradstock, MBBS, PhD, Ian D Lewis, MB, BS, PhD, Russell Saal, BAppSci, MMedSci, Lyle McMillen, BSc, PhD, Juliana Di Iulio, BAppSc, PhD, Diana Zannino, BSc, MSc, Andrew Grigg, MBBS

Blood (2013) 122 (21): 1444.

https://doi.org/10.1182/blood.V122.21.1444.1444

Published: 2013

NARROW

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial

Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL)

A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity

High Dose Cytarabine (HiDAC) and Fludarabine Without Anthracycline For Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): The Australasian Leukaemia and Lymphoma Group (ALLG) AMLM13 Study

Email alerts

ASH Publications

American Society of Hematology

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial

Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL)

A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity

High Dose Cytarabine (HiDAC) and Fludarabine Without Anthracycline For Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): The Australasian Leukaemia and Lymphoma Group (ALLG) AMLM13 Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only